本レポートは、世界の首位諸国における臨床試験件数および平均被験者数などに注目し、遺伝性血管性浮腫（HAE）（C1エステラーゼインヒビター欠損症）の臨床試験の概要を提供します。また、地域別、国別（G7 & E7）、段階別、進捗状況別、臨床試験の目標の達成状況別、スポンサーの種類別に、遺伝性血管性浮腫（HAE）（C1エステラーゼインヒビター欠損症）の臨床試験を分析します。さらに、臨床試験が進行中の主要薬剤の情報（進行中の臨床試験数に基づいて）を提供します。
本レポートは、GlobalData社の社内データベース（Pharma - 臨床試験データベース）から入手したデータを用いて作成されています。臨床試験は、世界の80を超えるさまざまな臨床試験レジストリ、会議、ジャーナル、ニュースなどから照合されています。臨床試験データベースは、ダイナミックなプロセスによって周期的に更新されます。
目次
Table of Contents
List of Tables
List of Figures
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials
Prominent Drugs
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Source
List of Tables
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Region, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Europe, Top Five Countries, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, North America, Top Countries, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Central and South America, Top Countries, 2021*
Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials, G7 Countries (%), 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, G7 Countries, Clinical Trials by Phase, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2021*
Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials, E7 Countries (%), 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, E7 Countries, Clinical Trials by Phase, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Phase, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials In Progress by Phase 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Trial Status, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, by End Point Status, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2016-2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Key Sponsors, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021*
List of Figures
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Region (%), 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, North America, Top Countries (%), 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2021*
Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials, G7 Countries (%), 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, G7 Countries, Clinical Trials by Phase, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2021*
Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials, E7 Countries (%), 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, E7 Countries, Clinical Trials by Phase, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Phase (%), 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials In Progress by Phase, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics, Global, Clinical Trials by Trial Status, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, by End Point Status, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2016-2020
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Key Sponsors, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2021*
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021*
GlobalData Methodology
